Cri­net­ic­s' stock jumps fol­low­ing promis­ing Ph2 da­ta in four pa­tients with rare ge­net­ic dis­or­der

Cri­net­ics Phar­ma­ceu­ti­cals shared Phase 2 da­ta in­ves­ti­gat­ing atumel­nant in pa­tients with con­gen­i­tal adren­al hy­per­pla­sia that showed the drug re­duced bio­mark­ers of the dis­ease.

The da­ta …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER